Abstract
Abstract
Background
In 2020, a research group published five linear longitudinal models, predict Expanded Prostate Cancer Index Composite-26 (EPIC-26) scores post-treatment for radical prostatectomy, external beam radiotherapy and active surveillance collectively in US patients with localized prostate cancer.
Methods
Our study externally validates the five prediction models for patient reported outcomes post-surgery for localised prostate cancer. The models’ calibration, fit, variance explained and discrimination (concordance-indices) were assessed. Two Australian validation cohorts 1 and 2 years post-prostatectomy were constructed, consisting of 669 and 439 subjects, respectively (750 in total). Patient reported function in five domains post-prostatectomy: sexual, bowel, hormonal, urinary incontinence and other urinary dysfunction (irritation/obstruction). Domain function was assessed using the EPIC-26 questionnaire.
Results
1 year post-surgery, R2 was highest for the sexual domain (35%, SD = 0.02), lower for the bowel (21%, SD = 0.03) and hormone (15%, SD = 0.03) domains, and close to zero for urinary incontinence (1%, SD = 0.01) and irritation/obstruction (− 5%, SD = 0.04). Calibration slopes for these five models were 1.04 (SD = 0.04), 0.84 (SD = 0.06), 0.85 (SD = 0.06), 1.16 (SD = 0.13) and 0.45 (SD = 0.04), respectively. Calibration-in-the-large values were − 2.2 (SD = 0.6), 2.1 (SD = 0.01), 5.1 (SD = 0.1), 9.6 (SD = 0.9) and 4.0 (SD = 0.2), respectively. Concordance-indices were 0.73, 0.70, 0.70, 0.58 and 0.62, respectively (all had SD = 0.01). Mean absolute error and root mean square error were similar across the validation and development cohorts. The validation measures were largely similar at 2 years post-surgery.
Conclusions
The sexual, bowel and hormone domain models validated well and show promise for accurately predicting patient reported outcomes in a non-US surgical population. The urinary domain models validated poorly and may require recalibration or revision.
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Reference30 articles.
1. Cancer Australia. Prostate cancer in Australia statistics. Canberra, Australia: Australian Government 2021 Available from: https://www.canceraustralia.gov.au/affected-cancer/cancer-types/prostate-cancer/statistics
2. Leslie SW, Soon-Sutton TL, IA R, Sajjad H, Siref LE, Prostate Cancer. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
3. Sebesta EM, Anderson CB. The surgical Management of Prostate Cancer. Semin Oncol. 2017;44(5):347–57. https://doi.org/10.1053/j.seminoncol.2018.01.003.
4. Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. Prostate Cancer Arnhem. Netherlands Euorp Assoc Urol. 2023; Available from: https://uroweb.org/guidelines/prostate-cancer
5. Weldring T, Smith SMS. Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs), vol. 6. Health Services Insights; 2013. p. HSI.S11093. https://doi.org/10.4137/hsi.s11093.